Opinion|Videos|January 13, 2025
Patient Case: AE Management in Practice With 1L IV Amivantamab
Panelists discuss practical insights and learning opportunities through interactive examination of a patient case.
Advertisement
Video content above is prompted by the following:
- Please present slides with patient case details and moderate brief discussion.
Advertisement
Related to this article
In the phase 1b CAMMA 1 trial, cevostamab plus pomalidomide and dexamethasone produced overall response rates of 86.2% to 88.0%.
Data from the phase 3 LITESPARK-011 trial support the FDA approval of belzutifan plus lenvatinib for adults with advanced clear cell renal cell carcinoma.
In the phase 1b portion of the MELT-MM trial, elranatamab plus mezigdomide produced a 100% overall response rate in relapsed/refractory multiple myeloma.
Xiuning Le, MD, PhD, discusses the confirmatory SOHO-02 trial needed to convert sevabertinib’s accelerated approval to full approval.
A pooled analysis of the AMY2009 and AMY3001 trials showed daratumumab plus VCd yielded hematologic complete responses in cardiac-involved AL amyloidosis.
Health Canada approved epcoritamab plus lenalidomide and rituximab for relapsed/refractory grade 1 to 3a follicular lymphoma, backed by the EPCORE FL-1 trial.
David R. Gandara, MD, discusses how EMPOWER-Lung 1’s findings in KRAS G12C-mutated disease should inform the design of combination trials.
Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
2
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
3
Daratumumab Combo Yields Responses in Cardiac-Involved AL Amyloidosis Trials
4
Epcoritamab Combo Receives Canadian Approval in R/R Follicular Lymphoma
5